Bioavailability involves the degree and velocity at which a drug is absorbed into the bloodstream, rendering it accessible to its designated tissue or organ. A drug's total bioavailability is less than one when administered through an extravascular route. Various physiological factors can limit the availability of medications before they reach the bloodstream. Absorption is influenced by food intake, and concurrent medications can alter absorption and first-pass metabolism. The drug termination can be influenced by intestinal motility, and the chemical breakdown of compounds may be impacted by the presence of intestinal micro flora.
Bioequivalence compares the bioavailability of distinct formulations of a given drug. When two formulations demonstrate bioequivalence, it is anticipated that they will generate comparable therapeutic effects. This is particularly important in generic drug development, where ensuring bioequivalence to the original branded product is essential for regulatory approval. Numerous factors, such as drug formulation, route of administration, and patient-specific characteristics, can exert an influence on both bioavailability and bioequivalence.
Title : Medical liver biopsy: Toward a personalized approach
Consolato M Sergi, Universities of Alberta and Ottawa, Canada
Title : Macitentan/tadalafil combination– An additional value in pharmacotherapy of pulmonary arterial hypertension
Miroslav Radenkovic, University of Belgrade, Serbia
Title : Ectopically expressed olfactory receptors as an untapped family of drug targets and discovery of agonists and antagonists of OR51E1, an understudied G protein-coupled receptor
Vladlen Slepak, University of Miami Miller School of Medicine, United States
Title : Mathematical modeling the disc diffusion test: Antibacterial activity of copper-doped SnO2
Paulo Cesar De Morais, Catholic University of Brasilia, Brazil
Title : Emerging formulation and delivery applications of Vitamin E TPGS
Andreas M Papas, Antares Health Products, United States
Title : The promise of nanotechnology in personalized & precision medicine: Drug discovery & development being partnered with nanotechnologies via the revolution at the nanoscale
Sergey Suchkov, The Russian University of Medicine and Russian Academy of Natural Science-Moscow, Russian Federation
Title : Personalized and Precision Medicine (PPM) as a unique healthcare model through design-inspired biotech- & biopharma-driven applications and upgraded business marketing to secure the human healthcare and biosafety
Sergey Suchkov, The Russian University of Medicine and Russian Academy of Natural Science-Moscow, Russian Federation
Title : Design and evaluation of exo-itc: A bilayer fibrous system for controlled exosome delivery in dermatological applications
Luis Jesus Villarreal Gomez, FCITEC - Universidad AutĂłnoma de Baja California, Mexico
Title : Antibody-proteases as translational tools of the next-step generation to be applied for biopharmacy-related and precision medical practice
Sergey Suchkov, The Russian University of Medicine and Russian Academy of Natural Science-Moscow, Russian Federation
Title : Understanding drug transport in plasma: The role of protein binding
Saad Tayyab, UCSI University, Malaysia